LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

SektorTervishoid

4.52 6.1

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.41

Max

4.52

Põhinäitajad
By Trading Economics
Sissetulek	-23M -37M
Müük	-20M 21M
Aktsiakasum	-0.58
Kasumimarginaal	-177.011
Töötajad	293
EBITDA	-17M -32M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+39.74% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	89M 276M
Eelmine avamishind	-1.58
Eelmine sulgemishind	4.52

Uudiste sentiment

By Acuity

50%

151 / 345 Pingereas Healthcare

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. mai 2026, 08:24 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25. mai 2026, 21:22 UTC

Tulu

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25. mai 2026, 20:50 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:20 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25. mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25. mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25. mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25. mai 2026, 12:56 UTC

Market Talk

Tulu

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25. mai 2026, 12:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero's Assets Look Strategic -- Market Talk

25. mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25. mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25. mai 2026, 10:05 UTC

Tulu

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25. mai 2026, 10:04 UTC

Tulu

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25. mai 2026, 10:03 UTC

Tulu

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25. mai 2026, 10:02 UTC

Tulu

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25. mai 2026, 10:01 UTC

Tulu

Tenaga Nasional 1Q Net Up 3.7% on Year

25. mai 2026, 10:00 UTC

Tulu

Tenaga Nasional 1Q Rev Up 6.6% on Year

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q EPS MYR0.1883

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Rev MYR17.1B

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Net MYR1.1B

25. mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25. mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25. mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25. mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

39.74% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD 39.74%

Kõrge 9 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

151 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.